Incorporating New Therapy Into Established Clinical Practice Guidelines
AbstractIn this issue of the Southern Medical Journal, McFarland et al have published a quite interesting article entitled "Place in Therapy for Liraglutide and Saxagliptin for Type 2 Diabetes."1 The authors describe and discuss the pharmacology and the utilization for these unique anti-diabetic drugs. Liraglutide, like exenatide, is a glucagon-like peptide-1 (GLP-1) receptor agonist that lowers blood sugar by potentiating glucose-mediated insulin production and reducing glucagon secretion. Normally, the secretion of the human incretin hormone GLP-1 is induced by the presence of nutrients like carbohydrates, proteins, and lipids, but these GLP-1 analogues can be used to stimulate insulin secretion by binding to the GLP-1 receptor. Saxagliptine acts by a related but different mechanism from liraglutide. Saxagliptine inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which is responsible for metabolizing the human incretin hormone GLP-1. Human incretin hormone GLP-1 normally has a half-life of less than two minutes, but in the presence of saxagliptine the GLP-1 half-life is significantly extended, thus allowing for greater stimulation of the pancreas to secrete insulin.2,3
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.